

MeRes100TM

Sirolimus Eluting BioResorbable Vascular Scaffold System

Meril

ri
More to Life




MeRes100TM

Sirolimus Eluting BioResorbable Vascular Scaffold System

Simply Sublime.

Next Generation BioResorbable Scaffold.




Size Matrix



Diameters - 2.50, 2.75, 3.00, 3.25, 3.50, 4.00, 4.50 mm

Lengths - 13, 16, 19, 24, 29, 32, 37, 40 mm

MeRes100 - BRS Enhanced Radiopacity





MeRes100 couplets of tri-axial RO markers at either end of the scaffold, gives a sense of virtual tubing and high operator comfort.




Distance from edge of Balloon RO marker (both proximal & distal) to edge of Scaffold RO = 1.3 mm

MeRes100 - BRS Best-in-Class Strut Thickness



MeRes100 is a 100 µm strut thickness scaffold with a propensity to minimize vascular injury & ensure early endothelialization.




Unique manufacturing process, novel hybrid design concept incorporating strut width variability allows for best-in-class, **DES-like strut thickness** in MeRes100.

MeRes100 - BRS Best-in-Class Crossing Profile



Average profile of 1.2 mm for Ø 3.00 mm



Unique crimping process, novel hybrid design concept incorporating low strut thickness allows for best-in-class, **DES-like crossing profile** in MeRes100.



MeRes-1 first-in-man safety and efficacy study in patients with single, de-novo coronary lesion (in up to two vessels) treated by MeRes100 - BRS.

N = 108, Prospective, Non-Randomized, Multi-Centre Study (16 Investigating sites in India)

Primary Demographics-Treatment Influencing Factors
Diabetics (28%), Hypertensive (42%), Dyslipidemics (13%), Smokers (17%)




Lesion characteristics-Lesion class A (7%), B1 (32%), B2 (56%), C (5%)

Post Dilatation 108 (100%) and **Device Success** 108 (100%)

Clinical Endpoint at 1-Year*

Clinical Endpoint MACE, n (%)	In-Hospital N = 108 (100%)	1-Month N = 108 (100%)	6-Months N = 108 (100%)	1-Year N= 107 (99%)
MACE Composite of	0 (0%)	0 (0%)	0 (0%)	1 (0.93%)
Cardiac Death	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Myocardial Infarction [@]	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Ischemia-driven TLR	0 (0%)	0 (0%)	0 (0%)	1 (0.93%)
Ischemia-driven TVR	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Scaffold Thrombosis^{\$}	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Non-cardiac death	0 (0%)	0 (0%)	1 [^] (0.9%)	0 (0%)

Late Lumen Loss (LLL)



*Seth A. et al, EuroIntervention 2017;13:415-423.


@ Myocardial Infarction defined as per WHO criteria. ^ Death due to aminophylline induced anaphylactic shock. \$ ARC defined criteria.

MeRes100 - BRS Implantation²

Mid LAD sub-occlusive stenosis and clinical outcome.

47 Years | Male | Non Diabetic | Non Hypertensive | Smoker | No Family History of CAD | Unstable Angina


Baseline




Post-Tx




6-Months f/up




2-Years f/up




Baseline



6-Months f/up



2-Years f/up



MeRes100 - BRS TECHNICAL SPECIFICATIONS

SCAFFOLD BACKBONE

Scaffold Material	: BioResorbable PLLA (Poly L-lactide)
Scaffold Strut Thickness	: 100 µm
Scaffold Diameters	: 2.50, 2.75, 3.00, 3.25, 3.50, 4.00, 4.50 mm
Scaffold Lengths	: 13, 16, 19, 24, 29, 32, 37, 40 mm

SCAFFOLD RO MARKERS

Tri-axial RO Markers	: Platinum (Couplets of tri-axial RO markers at either end, 120° apart from each other)
----------------------	---

TOP COAT-DRUG+POLYMER

Drug	: Sirolimus
Equivalent Drug Dose	: 1.25 µg / mm ²
Polymer	: BioResorbable PDLLA (Poly D, L-lactide)

DELIVERY SYSTEM

Delivery System	: Rapid Exchange
Nominal Pressure (NP)	: 9 atm
Rated Burst Pressure (RBP)	: 16 atm
Balloon Overhang	: < 0.5 mm
Shaft Outer Diameter	: Proximal 1.95 F / Distal 2.7 F
Radiopaque Markers	: 2 - Platinum / Iridium
Usable Catheter Length	: 140 cm
Guide Catheter Compatibility	: 6 F (Min. I D 0.070" / 1.8 mm)
Max. Guidewire	: 0.014" (0.36 mm)

MeRes100 - BRS ORDERING INFORMATION

Dia / Lengths	13 mm	16 mm	19 mm	24 mm
2.50 mm	MRS25013	MRS25016	MRS25019	MRS25024
2.75 mm	MRS27513	MRS27516	MRS27519	MRS27524
3.00 mm	MRS30013	MRS30016	MRS30019	MRS30024
3.25 mm	MRS32513	MRS32516	MRS32519	MRS32524
3.50 mm	MRS35013	MRS35016	MRS35019	MRS35024
4.00 mm	MRS40013	MRS40016	MRS40019	MRS40024
4.50 mm	MRS45013	MRS45016	MRS45019	MRS45024

Dia / Lengths	29 mm	32 mm	37 mm	40 mm
2.50 mm	MRS25029	MRS25032	MRS25037	MRS25040
2.75 mm	MRS27529	MRS27532	MRS27537	MRS27540
3.00 mm	MRS30029	MRS30032	MRS30037	MRS30040
3.25 mm	MRS32529	MRS32532	MRS32537	MRS32540
3.50 mm	MRS35029	MRS35032	MRS35037	MRS35040
4.00 mm	MRS40029	MRS40032	MRS40037	MRS40040
4.50 mm	MRS45029	MRS45032	MRS45037	MRS45040



Meril Life Sciences Pvt. Ltd.
Survey No. 135/139, Bilakhia House,
Muktanand Marg, Chala,
Vapi 396 191.
Gujarat. India.
T +91 260 305 2100
F +91 260 305 2125

Meril, Inc.
116, Village Boulevard, Suite 200,
Princeton, NJ 08540. USA.
T +1 609 951 2287
F +1 609 520 1702

Meril South America
Doc Med LTDA
Al. dos Tupiniquins,
1079 - Cep: 04077-003 - Moema.
Sao Paulo. Brazil.
T +55 11 3624 5935
F +55 11 3624 5936

Meril GmbH.
Bornheimer Strasse 135-137,
D-53119 Bonn.
Germany.
T +49 228 7100 4000
F +49 228 7100 4001

Meril Tibbi Cihazlar
Imalat Ve Ticaret A. S.
6, Mimar sinan Mah.,
Çavusbasi Cad. Özde Sok.
Aydin Eksi Is Merkezi Kat:1
Cekmekoy/Istanbul, Turkey.
T +90 53 2272 5172

OOO "Meril Medical"
St. Nauchney Proezd -19.
Moscow. 117246 Russia.
T +7 495 7727643

Meril SA Pty. Ltd.
6,Unit 7, Stoney Ridge Office Park,
Corner Witkoppen Road
And Waterford,
Paulshof - Johannesburg,
Gauteng - 2191, South Africa.
T +27 11 465 2049
F +27 86 471 7941

Meril Bangladesh Pvt. Ltd.
Union Heights-01,
55-2, Bir Uttam Qazi
Nuruzamman Sarak,
West Panthapath,
Dhaka - 1205, Bangladesh.
T +88 02 9122714 / 24

E askinfo@merillife.com
W www.merillife.com

MeRes100 is registered trademark
of Meril Life Sciences Pvt. Ltd.

1. OCT Image courtesy of Dr. Daniel Chamié, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil. 2. Data on file at Meril Life Sciences Pvt. Ltd.
Information for the use only in countries with applicable health authority product registrations.